The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.
 
Lu Si
No Relationships to Disclose
 
Meiyu Fang
Speakers' Bureau - Merck Sharp & Dohme; Novartis; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Novartis; Roche
 
Yu Chen
Speakers' Bureau - Merck Sharp & Dohme; Novartis; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Novartis; Roche
 
Lili Mao
No Relationships to Disclose
 
Peng Zhang
Speakers' Bureau - Merck Sharp & Dohme; Novartis; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Novartis; Roche
 
Jing Lin
Speakers' Bureau - Merck Sharp & Dohme; Novartis; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Novartis; Roche
 
Xue Bai
Other Relationship - Bristol-Myers Squibb
 
Xiao Cao
Employment - Shanghai Roche Pharmaceuticals
Travel, Accommodations, Expenses - Shanghai Roche Pharmaceuticals
 
Yi Chen
Employment - Shanghai Roche Pharmaceuticals
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere